Regulatory News In Brief
This article was originally published in The Gray Sheet
Executive Summary
Opened but unused SUDs: Comments on hospital practices associated with opened but unused single use devices (SUDs) are due by Nov. 26. Specific questions posed in the 1Aug. 28 notice on opened but unused SUDs include: what SUDs are typically resterilized because they are open but unused; how hospitals decide when an opened but unused SUD is contaminated; and whether hospitals have standard operating procedures for such determinations. The agency says it is seeking the information as part of a review of its policy on opened but unused SUDs, which are defined as single-use disposable devices that have not been used on a patient but whose sterility is in question. FDA is seeking comments from hospitals, original equipment manufacturers, reprocessors, professional organizations and other interested parties...
You may also be interested in...
Picture archiving and communications systems
July 27 FDA guidance on 510(k) submissions for the Class II devices is not applicable to either medical information systems for non-clinical data, or "image processing devices that utilize artificial intelligence or other techniques to identify abnormalities in medical images or assist in diagnosis," the document states
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.